{"transactions":[{"id":1947719,"issuer":{"id":109568,"kind":"organization","name":"NeuBase Therapeutics, Inc.","symbol":"NBSE"},"owners":[{"id":115435,"kind":"person","name":"Branning Todd P.","position":1,"cik":"0001765274","reported_name":"Branning Todd P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2023-03-17T16:11:24.000Z","date":"2023-03-16","kind":"grant","acquired":true,"shares":54200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock units to be settled by the issuance of one share of common stock for each restricted stock unit that is earned; 25% of which shall vest on March 16, 2024 and the remainder of which shall vest monthly thereafter until March 16, 2027, provided that vesting shall only occur on a scheduled vesting date if employment has not terminated prior to such vesting date, inclusive. Restricted stock units are subject to accelerated vesting, subject to certain conditions, in the event of a change of control of the Issuer."}],"balance_after":84200,"source":{"system":"sec-edgar","filing":"0001104659-23-033858","document":"tm239873d2_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1173281/000110465923033858/tm239873d2_4.xml","form_type":"4"}},{"id":2124627,"issuer":{"id":109568,"kind":"organization","name":"NeuBase Therapeutics, Inc.","symbol":"NBSE"},"owners":[{"id":115435,"kind":"person","name":"Branning Todd P.","position":1,"cik":"0001765274","reported_name":"Branning Todd P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock option (right to buy)","published_at":"2022-11-04T17:00:34.000Z","date":"2022-11-03","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"50% of the total shares shall vest on March 1, 2023, and the remaining shares shall vest on November 1, 2023, provided that vesting shall only occur on a scheduled vesting date if employment has not terminated prior to such vesting date, inclusive. Shares are subject to accelerated vesting in the event of a change of control of the Issuer, provided that employment has not terminated prior to such vesting date, inclusive."}],"balance_after":200000,"derivative":{"exercise_price":0.28,"expiration_date":"2032-11-03","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001104659-22-114954","document":"tm2229741d1_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1173281/000110465922114954/tm2229741d1_4.xml","form_type":"4"}},{"id":2323329,"issuer":{"id":109568,"kind":"organization","name":"NeuBase Therapeutics, Inc.","symbol":"NBSE"},"owners":[{"id":115435,"kind":"person","name":"Branning Todd P.","position":1,"cik":"0001765274","reported_name":"Branning Todd P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2022-03-21T16:06:00.000Z","date":"2022-03-18","kind":"purchase","acquired":true,"shares":10000,"price":1.81,"value":18100.0,"ownership":{"direct":true},"balance_after":30000,"source":{"system":"sec-edgar","filing":"0001104659-22-036105","document":"tm2210039-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1173281/000110465922036105/tm2210039-1_4seq1.xml","form_type":"4"}},{"id":2325044,"issuer":{"id":109568,"kind":"organization","name":"NeuBase Therapeutics, Inc.","symbol":"NBSE"},"owners":[{"id":115435,"kind":"person","name":"Branning Todd P.","position":1,"cik":"0001765274","reported_name":"Branning Todd P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2022-03-18T16:11:39.000Z","date":"2022-03-17","kind":"purchase","acquired":true,"shares":10000,"price":1.74,"value":17400.0,"ownership":{"direct":true},"balance_after":20000,"source":{"system":"sec-edgar","filing":"0001104659-22-035572","document":"tm229793-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1173281/000110465922035572/tm229793-1_4seq1.xml","form_type":"4"}},{"id":2325043,"issuer":{"id":109568,"kind":"organization","name":"NeuBase Therapeutics, Inc.","symbol":"NBSE"},"owners":[{"id":115435,"kind":"person","name":"Branning Todd P.","position":1,"cik":"0001765274","reported_name":"Branning Todd P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2022-03-18T16:11:39.000Z","date":"2022-03-16","kind":"purchase","acquired":true,"shares":10000,"price":1.62,"value":16200.0,"ownership":{"direct":true},"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001104659-22-035572","document":"tm229793-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1173281/000110465922035572/tm229793-1_4seq1.xml","form_type":"4"}},{"id":2439042,"issuer":{"id":109568,"kind":"organization","name":"NeuBase Therapeutics, Inc.","symbol":"NBSE"},"owners":[{"id":115435,"kind":"person","name":"Branning Todd P.","position":1,"cik":"0001765274","reported_name":"Branning Todd P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee stock option (right to buy)","published_at":"2022-01-10T19:19:44.000Z","date":"2022-01-10","kind":"grant","acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4th of the total shares shall vest on the first anniversary of the effective date of employment, and 1/36th of the remaining shares shall vest on a monthly basis starting on the first anniversary of the effective date of employment; provided that vesting shall only occur on a scheduled vesting date if employment has not terminated prior to such vesting date, inclusive."}],"balance_after":300000,"derivative":{"exercise_price":2.52,"expiration_date":"2032-01-10","underlying":"Common stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001104659-22-002844","document":"tm222244d2_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1173281/000110465922002844/tm222244d2_4.xml","form_type":"4"}},{"id":2889908,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":115435,"kind":"person","name":"Branning Todd P.","position":1,"cik":"0001765274","reported_name":"Branning Todd P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-29T16:28:28.000Z","date":"2021-01-28","kind":"grant","acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest with respect to 25% of the shares of common stock on January 28, 2022, and will vest with respect to the remaining\nshares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the\napplicable vesting dates."}],"balance_after":60000,"derivative":{"exercise_price":39.11,"expiration_date":"2031-01-27","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001209191-21-006095","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1765274/000120919121006095/doc4.xml","form_type":"4"}},{"id":3084127,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":115435,"kind":"person","name":"Branning Todd P.","position":1,"cik":"0001765274","reported_name":"Branning Todd P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-07-13T16:50:20.000Z","date":"2020-07-13","kind":"grant","acquired":true,"shares":85000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest with respect to one-fourth of the shares of common stock on July 13, 2021, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates."}],"balance_after":85000,"derivative":{"exercise_price":29.43,"expiration_date":"2030-07-12","underlying":"Common Stock","underlying_shares":85000},"source":{"system":"sec-edgar","filing":"0001209191-20-042292","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1765274/000120919120042292/doc4.xml","form_type":"4"}},{"id":3238388,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":115435,"kind":"person","name":"Branning Todd P.","position":1,"cik":"0001765274","reported_name":"Branning Todd P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and CFO"}}],"security":"Performance-Based Restricted Stock Units","published_at":"2020-03-03T01:08:16.000Z","date":"2020-02-27","kind":"grant","acquired":true,"shares":166226,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."},{"field":"shares","element":"transactionShares","label":"F4","text":"Represents the maximum number of shares issuable under the performance-based restricted stock units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the performance-based restricted stock units are earned and eligible to vest upon the Issuer's Class A Common Stock achieving an average closing price per share of $8 or higher for 60 consecutive calendar days during the three-year performance period. An additional 12.5% of the performance-based restricted stock units are earned and eligible to vest upon the Issuer's Class A Common Stock achieving an average closing price per share of $10, $12, $14, $16, $18 and $20, respectively, for 60 consecutive calendar days during the three-year performance period. For average 60-day closing stock prices between $12 and $20 per share, the number of performance-based restricted stock units that become earned will be determined using straight line interpolation. Any earned performance-based restricted stock units vest in full on February 28, 2023, the last day of the performance period."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"25% of the performance-based restricted stock units are earned and eligible to vest upon the Issuer's Class A Common Stock achieving an average closing price per share of $8 or higher for 60 consecutive calendar days during the three-year performance period. An additional 12.5% of the performance-based restricted stock units are earned and eligible to vest upon the Issuer's Class A Common Stock achieving an average closing price per share of $10, $12, $14, $16, $18 and $20, respectively, for 60 consecutive calendar days during the three-year performance period. For average 60-day closing stock prices between $12 and $20 per share, the number of performance-based restricted stock units that become earned will be determined using straight line interpolation. Any earned performance-based restricted stock units vest in full on February 28, 2023, the last day of the performance period."}],"balance_after":166226,"derivative":{"underlying":"Class A Common Stock","underlying_shares":166226},"source":{"system":"sec-edgar","filing":"0000899243-20-006627","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000089924320006627/doc4.xml","form_type":"4"}},{"id":3238387,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":115435,"kind":"person","name":"Branning Todd P.","position":1,"cik":"0001765274","reported_name":"Branning Todd P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and CFO"}}],"security":"Restricted Stock Units","published_at":"2020-03-03T01:08:16.000Z","date":"2020-02-27","kind":"grant","acquired":true,"shares":83113,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units vest in four equal annual installments beginning on February 27, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units vest in four equal annual installments beginning on February 27, 2021."}],"balance_after":83113,"derivative":{"underlying":"Class A Common Stock","underlying_shares":83113},"source":{"system":"sec-edgar","filing":"0000899243-20-006627","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000089924320006627/doc4.xml","form_type":"4"}},{"id":3304183,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":115435,"kind":"person","name":"Branning Todd P.","position":1,"cik":"0001765274","reported_name":"Branning Todd P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and CFO"}}],"security":"Restricted Stock Units","published_at":"2020-01-23T22:42:16.000Z","date":"2020-01-22","kind":"exercise","acquired":false,"shares":20096,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On January 22, 2019, the reporting person was granted 80,386 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. The restricted stock units do not expire."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On January 22, 2019, the reporting person was granted 80,386 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. The restricted stock units do not expire."}],"balance_after":60290,"derivative":{"underlying":"Class A Common Stock","underlying_shares":20096},"source":{"system":"sec-edgar","filing":"0001209191-20-004719","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000120919120004719/doc4.xml","form_type":"4"}},{"id":3304182,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":115435,"kind":"person","name":"Branning Todd P.","position":1,"cik":"0001765274","reported_name":"Branning Todd P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and CFO"}}],"security":"Class A Common Stock","published_at":"2020-01-23T22:42:16.000Z","date":"2020-01-22","kind":"tax_withholding","acquired":false,"shares":7311,"price":5.13,"value":37505.43,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units."}],"balance_after":12785,"source":{"system":"sec-edgar","filing":"0001209191-20-004719","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000120919120004719/doc4.xml","form_type":"4"}},{"id":3304181,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":115435,"kind":"person","name":"Branning Todd P.","position":1,"cik":"0001765274","reported_name":"Branning Todd P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and CFO"}}],"security":"Class A Common Stock","published_at":"2020-01-23T22:42:16.000Z","date":"2020-01-22","kind":"exercise","acquired":true,"shares":20096,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."}],"balance_after":20096,"source":{"system":"sec-edgar","filing":"0001209191-20-004719","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000120919120004719/doc4.xml","form_type":"4"}},{"id":3371423,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":115435,"kind":"person","name":"Branning Todd P.","position":1,"cik":"0001765274","reported_name":"Branning Todd P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Stock Option","published_at":"2019-11-14T22:26:09.000Z","date":"2019-11-13","kind":"grant","acquired":true,"shares":163666,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option.  The option was originally granted on January 22, 2019, and will vest in four equal annual installments beginning on January 22, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option.  The option was originally granted on January 22, 2019, and will vest in four equal annual installments beginning on January 22, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option.  The option was originally granted on January 22, 2019, and will vest in four equal annual installments beginning on January 22, 2020."}],"balance_after":163666,"derivative":{"exercise_price":2.75,"expiration_date":"2029-01-22","underlying":"Class A Common Stock","underlying_shares":163666},"source":{"system":"sec-edgar","filing":"0001723128-19-000127","document":"wf-form4_157377035410885.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000172312819000127/wf-form4_157377035410885.xml","form_type":"4"}},{"id":3371422,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":115435,"kind":"person","name":"Branning Todd P.","position":1,"cik":"0001765274","reported_name":"Branning Todd P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Stock Option","published_at":"2019-11-14T22:26:09.000Z","date":"2019-11-13","kind":"disposition_to_issuer","acquired":false,"shares":163666,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option.  The option was originally granted on January 22, 2019, and will vest in four equal annual installments beginning on January 22, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option.  The option was originally granted on January 22, 2019, and will vest in four equal annual installments beginning on January 22, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option.  The option was originally granted on January 22, 2019, and will vest in four equal annual installments beginning on January 22, 2020."}],"balance_after":0,"derivative":{"exercise_price":12.44,"expiration_date":"2029-01-22","underlying":"Class A Common Stock","underlying_shares":163666},"source":{"system":"sec-edgar","filing":"0001723128-19-000127","document":"wf-form4_157377035410885.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000172312819000127/wf-form4_157377035410885.xml","form_type":"4"}},{"id":3688155,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":115435,"kind":"person","name":"Branning Todd P.","position":1,"cik":"0001765274","reported_name":"Branning Todd P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2019-01-24T22:45:49.000Z","date":"2019-01-22","kind":"grant","acquired":true,"shares":80386,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vest in four equal annual installments beginning on January 22, 2020 and have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units vest in four equal annual installments beginning on January 22, 2020 and have no expiration date."}],"balance_after":80386,"derivative":{"underlying":"Class A Common Stock","underlying_shares":80386},"source":{"system":"sec-edgar","filing":"0001723128-19-000019","document":"wf-form4_154836993308270.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000172312819000019/wf-form4_154836993308270.xml","form_type":"4"}},{"id":3688154,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":115435,"kind":"person","name":"Branning Todd P.","position":1,"cik":"0001765274","reported_name":"Branning Todd P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Stock Option","published_at":"2019-01-24T22:45:49.000Z","date":"2019-01-22","kind":"grant","acquired":true,"shares":163666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in four equal annual installments beginning on January 22, 2020."}],"balance_after":163666,"derivative":{"exercise_price":12.44,"expiration_date":"2029-01-22","underlying":"Class A Common Stock","underlying_shares":163666},"source":{"system":"sec-edgar","filing":"0001723128-19-000019","document":"wf-form4_154836993308270.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000172312819000019/wf-form4_154836993308270.xml","form_type":"4"}}]}